DUBLIN, November 18, 2025 — Leads & Copy — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will participate in Citi’s 2025 Global Healthcare Conference.
Company management will participate in a fireside chat on Tuesday, December 2, 2025, at 6:45 a.m. PST / 9:45 a.m. EST / 2:45 p.m. GMT.
An audio webcast of the fireside chat will be available via the Investors section of the Jazz Pharmaceuticals website. A replay of the webcast will be archived on the website for 30 days.
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company innovating to transform the lives of patients and their families. The company develops life-changing medicines for people with serious diseases with limited or no therapeutic options.
Jazz has a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. The company’s patient-focused and science-driven approach powers pioneering research and development advancements across its robust pipeline of innovative therapeutics in oncology and neuroscience.
Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries.
Investors can contact Jack Spinks, Executive Director, Investor Relations, at InvestorInfo@jazzpharma.com or at Ireland +353 1 634 3211 or U.S. +1 650 496 2717. Media contact is Kristin Bhavnani, Head of Global Corporate Communications, at CorporateAffairsMediaInfo@jazzpharma.com or at Ireland +353 1 637 2141 or U.S. +1 215 867 4948.
Source: Jazz Pharmaceuticals plc
